 | ProQR Therapeutics NV (NASDAQ:PRQR) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - July 10 at 1:38 AM |
 | ProQR Therapeutics (NASDAQ:PRQR) Cut to "Sell" at BidaskClub
www.marketbeat.com - July 7 at 1:14 AM |
 | News Flash: Analysts Just Made A Stunning Upgrade To Their ProQR Therapeutics N.V. (NASDAQ:PRQR) Forecasts
finance.yahoo.com - June 29 at 9:33 AM |
| ProQR Therapeutics (NASDAQ:PRQR) Stock Rating Reaffirmed by Chardan Capital
www.americanbankingnews.com - June 24 at 7:00 AM |
| Hedge Funds Souring On ProQR Therapeutics NV (PRQR)
finance.yahoo.com - June 22 at 7:35 PM |
| 5 Must-Buy Low-Beta Stocks Flying High in a Volatile Market
finance.yahoo.com - June 22 at 9:31 AM |
| Zacks.com featured highlights include: Frontline, iClick Interactive Asia, Avenue Therapeutics, ProQR Therapeutics and BJ???s Wholesale Club
finance.yahoo.com - June 18 at 8:51 PM |
| ProQR Therapeutics NV (NASDAQ:PRQR) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 15 at 1:53 AM |
| ProQR Announces Expert Perspectives Conference Call Series
finance.yahoo.com - June 12 at 7:49 AM |
 | BRIEF-ProQR Announces Virtual Presentation Of Phase 1/2 Sepofarsen Data
www.reuters.com - June 8 at 12:55 PM |
|
| ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO)
finance.yahoo.com - June 8 at 7:48 AM |
| How ProQR (PRQR) Stock Stands Out in a Strong Industry
finance.yahoo.com - May 29 at 1:39 PM |
| BRIEF-ProQR Therapeutics Announces First Quarter 2020 Financial Results
www.reuters.com - May 7 at 4:02 PM |
| ProQR Announces First Quarter 2020 Operating and Financial Results
finance.yahoo.com - May 7 at 4:02 PM |
| ProQR (PRQR) Reports Q1 Loss, Lags Revenue Estimates
finance.yahoo.com - May 7 at 4:02 PM |
| Does ProQR Therapeutics (NASDAQ:PRQR) Have A Healthy Balance Sheet?
finance.yahoo.com - April 28 at 10:04 AM |
 | ProQR Therapeutics N.V.
www.marketwatch.com - April 25 at 11:39 PM |
 | Covid-19 pandemic to impact timelines for ProQR Therapeutics's pipeline; announces interim analysis from Phase 1/2 trial of QR-421a
seekingalpha.com - March 31 at 5:17 PM |
| ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update
finance.yahoo.com - March 31 at 8:19 AM |
| ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome
finance.yahoo.com - March 25 at 5:55 PM |
| How Much Did ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Pocket Last Year?
finance.yahoo.com - February 28 at 3:17 PM |
| ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update
finance.yahoo.com - February 26 at 8:03 AM |
| ProQR to Present at Cowen and Company 40th Annual Health Care Conference
finance.yahoo.com - February 24 at 8:39 AM |
 | Stock To Watch: ProQR Therapeutics (PRQR)
www.nasdaq.com - February 11 at 2:56 PM |
 | My Retina Tracker Program is the highest volume IRD genetic testing program in the U.S.
www.globenewswire.com - February 6 at 9:31 AM |
| ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases
finance.yahoo.com - February 6 at 9:31 AM |
| ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a
finance.yahoo.com - January 30 at 9:33 AM |
| Did Business Growth Power ProQR Therapeutics's (NASDAQ:PRQR) Share Price Gain of 119%?
finance.yahoo.com - December 23 at 4:14 PM |
| Did Business Growth Power ProQR Therapeutics's (NASDAQ:PRQR) Share Price Gain of 119%?
finance.yahoo.com - December 23 at 4:14 PM |
| Did Hedge Funds Drop The Ball On ProQR Therapeutics NV (PRQR) ?
finance.yahoo.com - December 17 at 6:19 PM |
|
| Dosing underway in study of ProQR's QR-1123 for vision loss disorder
seekingalpha.com - December 11 at 1:16 PM |
| ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa
finance.yahoo.com - December 11 at 8:15 AM |
| Moderna: Undervalued As The Promising Pipeline Awaits Collaborations
seekingalpha.com - November 21 at 7:53 PM |
 | ProQR Therapeutics Takes a Big Step Forward With Its Latest FDA Approval
www.msn.com - November 21 at 9:34 AM |
| ProQR Therapeutics on watch after FDA win
seekingalpha.com - November 21 at 9:34 AM |
| ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
finance.yahoo.com - November 21 at 9:34 AM |
| ProQR shares rises on FDA orphan drug designation
finance.yahoo.com - November 21 at 9:34 AM |
| ProQR to Present at Upcoming Scientific Conferences
finance.yahoo.com - November 18 at 8:20 AM |
| ProQR to Present at Upcoming Investor Conferences
finance.yahoo.com - November 13 at 8:42 AM |
 | Biotech Stock Mailbag: ProQR, Vertex Pharma, Tekmira, Agios
www.thestreet.com - November 8 at 11:41 PM |
| ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019
finance.yahoo.com - November 6 at 8:52 AM |
| Will ProQR Therapeutics Continue to Surge Higher?
finance.yahoo.com - October 23 at 10:52 AM |
| ProQR prices stock offering; shares down 12% after hours
seekingalpha.com - October 16 at 12:20 AM |
| ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares
finance.yahoo.com - October 16 at 12:20 AM |
| ProQR's sepofarsen nabs Rare Pediatric Disease status in U.S. for LCA10
seekingalpha.com - October 15 at 7:19 PM |
| ProQR Therapeutics (PRQR) Sepofarsen Phase 1/2 Trial Topline Results - Slideshow
seekingalpha.com - October 11 at 6:44 PM |
 | ProQR Therapeutics N.V.: ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients
www.finanznachrichten.de - October 10 at 7:26 AM |
| ProQR's sepofarsen shows positive action in Phase 1/2 study in LCA10
seekingalpha.com - October 10 at 7:26 AM |
| ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients
finance.yahoo.com - October 10 at 7:26 AM |
| ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO
finance.yahoo.com - October 7 at 9:04 AM |
